Revised MRPs of 1,364 anti-cancer formulations come into effect; consumers to save US$ 372.48 million annually
- IBEF
- November 10, 2026
Revised maximum retail prices (MRPs) of 1,364 anti-cancer formulations came into effect on November 9, 2026, following the implementation of price-control measures by the National Pharmaceutical Pricing Authority (NPPA), under the Department of Pharmaceuticals. The revised prices are expected to generate annual savings of approximately Rs. 3,540.38 crore (US$ 372.48 million) for consumers. The NPPA capped trade margins on the maximum retail prices of 137 anti-cancer drugs, based on recommendations submitted by an Expert Committee constituted by the Directorate General of Health Services (DGHS), Ministry of Health and Family Welfare, on October 17, 2026. According to the Ministry of Chemicals and Fertilizers, 85 pharmaceutical companies had reported revised MRPs for 1,364 formulations across 121 drugs as of November 8, 2026.
The revised prices have resulted in reductions of more than 50% for 679 brands, with the highest reported price reduction reaching 96.45%. Chemists and hospital pharmacies are not permitted to charge consumers above the revised MRPs. Consumers can verify medicine prices through the revised MRP printed on product packaging, the Pharma Sahi Daam mobile application or the official NPPA website. Complaints regarding overcharging and other medicine-pricing issues can be submitted through the Pharma Jan Samadhan portal or the NPPA helpline at 1800-111-255. The measure is expected to improve the affordability and accessibility of essential cancer medicines while reducing the financial burden on patients and their families.
Disclaimer: This information has been collected through secondary research and IBEF is not responsible for any errors in the same.
Partners
